Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Cancer Core Europe: where did it come from and what is its future?

Prof Julio Celis - Danish Cancer Society Research Center, Copenhagen, Denmark

Cancer Core Europe: where did it come from and what is its future? ( Prof Julio Celis - Danish Cancer Society Research Center, Copenhagen, Denmark )

Highlights of the EurocanPlatform Project

Highlights of the EurocanPlatform Project ( )

Cancer Core Europe: one year on (full version)

Prof Alexander Eggermont - Gustave Roussy, Villejuf, France

Cancer Core Europe: one year on (full version) ( Prof Alexander Eggermont - Gustave Roussy, Villejuf, France )

Treating elderly patients at the molecular level

Dr Christophe Massard - Institut Gustave Roussy, Paris, France

Treating elderly patients at the molecular level ( Dr Christophe Massard - Institut Gustave Roussy, Paris, France )

Four molecular subtypes identified in pancreatic cancer

Dr David Chang - University of Glasgow, Glasgow, UK

Four molecular subtypes identified in pancreatic cancer ( Dr David Chang - University of Glasgow, Glasgow, UK )

NCRI 2015 highlights

Prof Charles Swanton - Cancer Research UK's London Research Institute, London...

NCRI 2015 highlights ( Prof Charles Swanton - Cancer Research UK's London Research Institute, London, UK )

Prognostic value of BRAFV600 mutations in stage 3 cutaneous melanoma patients

Prof Philippe Saiag - University of Versailles, Versailles, France

Prognostic value of BRAFV600 mutations in stage 3 cutaneous melanoma patients ( Prof Philippe Saiag - University of Versailles, Versailles, France )

Anti-PD1 or tyrosine kinase inhibitors?

Dr Mark Middleton - University of Oxford, Oxford, UK

Anti-PD1 or tyrosine kinase inhibitors? ( Dr Mark Middleton - University of Oxford, Oxford, UK )

Disruptive technologies in cancer

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Disruptive technologies in cancer ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Latest from the CoBRIM study

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Latest from the CoBRIM study ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Anti-PD-1 or anti-CTLA-4 in first line therapy?

Prof Claus Garbe - University of Tübingen, Tübingen, Germany

Anti-PD-1 or anti-CTLA-4 in first line therapy? ( Prof Claus Garbe - University of Tübingen, Tübingen, Germany )

Long response and long responders in melanoma immunology

Prof Georgina Long - University of Sydney, Sydney, Australia

Long response and long responders in melanoma immunology ( Prof Georgina Long - University of Sydney, Sydney, Australia )

More from ecancer